The company is collaborating with the Ontario Bioscience Innovation Organization (OBIO) to evaluate its core technology at Health Sciences North in Greater Sudbury
Flosonics Medical’s wireless, wearable Doppler ultrasound system was selected as one of the first eight Early Adopter Health Network (EAHN) innovation projects by the Ontario Bioscience Innovation Organization (OBIO).
As part of the EAHN program, OBIO has partnered each of the eight leading technologies in the first cohort with Ontario health care organizations to complete rapid evaluations over a period of up to 12 months.
These partnerships will help drive innovation in the Canadian health science industry into the Ontario health care system through an end-to-end process, extending from technology evaluation to commercialization.
Flosonics Medical, a scaling medical device company headquartered in Sudbury, Ontario, is collaborating with OBIO to evaluate FloPatch at Health Sciences North.
The medical device enables rapid, repeatable, and trusted hemodynamic assessments throughout the continuum of care, including emergency department and intensive care unit patients with COVID-19.
“Flosonics Medical is pleased to partner with OBIO and Health Sciences North to introduce its FloPatch technology for remote monitoring applications,” said Joe Eibl, co-founder and CEO of Flosonics Medical.
EAHN evaluates innovations across the health technology spectrum, from medical devices and COVID-19 solutions to digital tools that follow patients on their care journeys.
The goal of the program is to get these innovative technologies into the health care system faster and disseminated.
Since the call for applications on May 14, OBIO evaluated over 70 applications from across Canada and selected the most commercial-ready technologies to participate in the program.
Flosonics Medical was chosen alongside eight other health sciences companies across the province, including Awake Labs, Ironstone Development, Huron Digital Pathology, Hypercare, KA Imaging, Synaptive Medical and Therapeutic Monitoring Systems.
Technology evaluations will be taking place at health organizations throughout Ontario, including the Centre for Addiction and Mental Health (CAMH), The Ottawa Hospital, and University Health Network (UHN).
“OBIO’s EAHN gives Canadian health technology companies an opportunity to access local markets before expanding globally and a strong reason to anchor themselves in Canada,” said Gail Garland, President and CEO of OBIO.
“With EAHN, OBIO is partnering innovators and health organizations to get innovative technologies, including COVID-19-related technologies, into the health care system and to patients faster than ever before, realizing both the health and economic benefits that health science innovators within our own country can offer.”
Collaboration between the health science industry and Ontario’s health care system creates the opportunity to leverage health care as an economic driver for the province.
“Ontario is home to some of the world’s most innovative companies with a strong history of developing state of the art health care solutions,” said Vic Fedeli, Minister of Economic Development, Job Creation and Trade.
“Our economic recovery will rely on the growth of these companies and the good jobs they create. As we continue to emerge from the pandemic, programs like OBIO’s EAHN get innovative health technologies into our health care system and will ensure the growth of the domestic health science industry in Ontario.”
OBIO will also continue to work with all EAHN applicants to prepare them for readiness for future EAHN cohorts.
OBIO is a not-for-profit, membership-based innovation organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies positioning Canada as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment, community, academia, the health system and government. For more information visit www.obio.ca.
EAHN is supported through the Federal Economic Development Agency for Southern Ontario as part of a $6.2 million investment in OBIO to boost investment and market access for companies looking to commercialize their medical innovations. For over 10 years, FedDev Ontario has actively worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation and growth in Canada’s most populous region. For more information, visit www.feddevontario.gc.ca.